Zanubrutinib associated with higher 3-year PFS versus acalabrutinib-venetoclax in treatment-naive CLL
Zanubrutinib outperforms combo therapy for early leukemia
This post hoc indirect comparison analyzed treatment-naive chronic lymphocytic leukemia patients without del(17p) from phase 3 RCTs. Zanubru…
A single pill for early leukemia may work better than taking multiple drugs, offering a simpler and more effective option for patients who w…
BR regimen shows survival outcomes in newly diagnosed Waldenstroms Macroglobulinemia patients
A Rare Blood Cancer With an 8-Year Survival: What Real-World Data Shows
This single-center retrospective analysis evaluated 89 newly diagnosed Waldenstroms Macroglobulinemia patients treated with the BR regimen. …
New real-world data shows patients with the rare blood cancer Waldenstrom's macroglobulinemia live a median of over 8 years after diagnosis.